Iovance Biotherapeutics, Inc. (IOVA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Iovance Biotherapeutics, Inc. (IOVA) is up 48.7% since the beginning of the year. At $4 per share, IOVA is trading 27.9% below its 52-week high of $6. Investors who bought $1,000 worth of IOVA shares 5 years ago would now be looking at an investment worth $164.

Iovance Biotherapeutics, Inc. (IOVA) has returned 48.72% so far this year and 105.05% over the past 12 months. Over the last ten years, IOVA has returned -6.39% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Oct 15, 2010, IOVA's average daily return is +0.30%, while the average monthly return is +2.39%. At this rate, an investment would double in approximately 2.4 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jul 2013 with a return of +250.0%, while the worst month was Apr 2013 at -66.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, IOVA closed higher 43% of trading days. The best single day was May 3, 2013 with a return of +200.0%, while the worst single day was May 7, 2013 at -83.3%.

Iovance Biotherapeutics, Inc. has an annualized alpha of 81.75%, beta of 1.27, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 15, 2010.

• This stock participated in 174.71% of S&P 500 Index downside but only 30.76% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IOVA ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Iovance Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Iovance Biotherapeutics, Inc. was 99.37%, occurring on Apr 12, 2013. The portfolio has not yet recovered.

The current Iovance Biotherapeutics, Inc. drawdown is 97.45%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Iovance Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Iovance Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.